Grown Rogue International (GRUSF) Raw Materials (2024 - 2026)

Grown Rogue International's (GRUSF) quarterly Raw Materials came in at $730505.0 in Q1 2026, down 29.68% quarter-over-quarter from $1.0 million in Q4 2025.

Grown Rogue International (GRUSF) Raw Materials (2024 - 2026) Analysis & Trends

Grown Rogue International's Raw Materials history runs 3 years deep, the most recent figure standing at $730505.0 for Q1 2026.

  • On a quarterly basis, Raw Materials changed N/A year-over-year to $730505.0 in Q1 2026; TTM through Mar 2026 was $730505.0, a N/A change from a year earlier, with the FY2025 full-year figure at $1.0 million, up 60.41% from the prior year.
  • Raw Materials declined to $730505.0 in Q1 2026 per GRUSF's latest filing, from $1.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.0 million in Q4 2025 and bottomed at $647630.0 in Q4 2024.
  • The 3-year median for Raw Materials is $744138.5 (2025), against an average of $793695.8.
  • Biggest YoY gain for Raw Materials was 60.41% in 2025; the steepest drop was 60.41% in 2025.
  • Year by year, Raw Materials stood at $647630.0 in 2024, then jumped by 60.41% to $1.0 million in 2025, then decreased by 29.68% to $730505.0 in 2026.
  • Per Business Quant, the three latest GRUSF Raw Materials figures stand at $730505.0 (Q1 2026), $1.0 million (Q4 2025), and $757772.0 (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Grown Rogue International 99.97 Mn 92.67 Mn 3.96 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 730,505.00
Dec 31, 2025 1.04 Mn
Jun 30, 2025 757,772.00
Dec 31, 2024 647,630.00